Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol
Crossref DOI link: https://doi.org/10.1186/s13014-016-0583-0
Published Online: 2016-01-20
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ritter, M.
Teudt, I. U.
Meyer, J. E.
Schröder, U.
Kovács, G.
Wollenberg, B.